No­vo Nordisk and Hims ap­pear to have buried the hatch­et. Hims & Hers is go­ing to sell the brand-name No­vo weight loss drugs on its web­site at a dis­count, and says it’s go­ing to lim­it com­pound­ing. No­vo moved to drop its law­suit against Hims. Reg­u­la­tors seem hap­py. But who came out ahead in the deal?

The End­points News health tech team (+ friends!) is tak­ing over Post-Hoc Live to­day at 11:30 a.m. ET to break down where the bal­ance falls. I’ll be joined by End­points health tech cor­re­spon­dent Shel­by Liv­ingston, who’s cov­ered the Hims saga ex­ten­sive­ly, and End­points’ No­vo ex­pert and se­nior bio­phar­ma jour­nal­ist Eliz­a­beth Cairns.

We’ll be live on YouTube here, and you can set a cal­en­dar re­minder for show­time.

I’m ex­cit­ed to talk about the win­ners and losers in this whole saga, what it means for the com­pound­ing and weight loss drug ecosys­tems more broad­ly, and if we think the less-com­pound­ing promise from Hims is ac­tu­al­ly go­ing to stick.

See you soon!

— Ly­dia Ram­sey Pflanz­er